Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591654 · ClinicalTrials.gov registry record · Early Phase 1
MRI and PET to Assess Pembrolizumab Response
A Early Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT02591654 is a Early Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 6 participants.
The verdict
NCT02591654, a Early Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to test two imaging techniques, one called whole body (WB) diffusion weighted (DWI) magnetic resonance imaging (MRI) (WB-DWI MRI), and another called Fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography (PET) (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with metastatic melanoma receiving Pembrolizumab (MK-3475).
Interventions
- DRUG Pembrolizumab
- DRUG FLT PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10 |
| Est. Completion | 2022-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02591654
The ClinicalTrials.gov registry entry for NCT02591654 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02591654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02591654 about?
NCT02591654 is a clinical study titled "MRI and PET to Assess Pembrolizumab Response". The purpose of this study is to test two imaging techniques, one called whole body (WB) diffusion weighted (DWI) magnetic resonance imaging (MRI) (WB-DWI MRI), and another called Fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography (PET) (F-18-FLT PET). The goal is to see whether the...
What is the current status of trial NCT02591654?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2015-10. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02591654?
The interventions under investigation include: Pembrolizumab (DRUG), FLT PET (DRUG).
Who is sponsoring clinical trial NCT02591654?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.